Most common (≥5%) all-cause adverse events through Week 52 (safety population).
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Most_common_8805_5_all_cause_adverse_events_through_Week_52_safety_population_/165823
下载链接
链接失效反馈官方服务：
资源简介：
*Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be less than the row total.doi:10.1371/journal.pone.0054279.t003
创建时间：
2015-12-02
